MC3R

MC3R is the melanocortin receptor subtype expressed primarily in the hypothalamus and limbic system that modulates energy balance, nutrient partitioning, and cardiovascular autonomic tone - functions largely distinct from MC4R's role in satiety. MC3R activation promotes energy efficiency and fat storage in lean states, and MC3R-deficient mice develop late-onset obesity with increased fat mass on a standard diet even with normal food intake. AgRP acts as an endogenous antagonist/inverse agonist at both MC3R and MC4R. MC3R is also expressed in the heart, gut, and immune cells, where it suppresses cytokine release. No MC3R-selective drug is approved, but the receptor is emerging as a target for metabolic and inflammatory diseases.

MC3R (chromosome 20q13.32, 360 aa) binds all POMC-derived melanocortins - α-MSH, β-MSH, γ-MSH, and ACTH - with high affinity, through the conserved HFRW core tetrapeptide making contact with TM3 (Asp154), TM6, and ECL2. γ-MSH (which has minimal activity at MC1R and MC2R) is the highest-potency endogenous agonist at MC3R (EC₅₀ ~3 nM). Primary signaling: Gs → adenylyl cyclase → cAMP → PKA; some Gq/Ca²⁺ coupling at high receptor density. Endogenous antagonists ASIP and AgRP compete at the orthosteric site; AgRP acts as an inverse agonist (suppresses constitutive activity). MC3R lacks constitutive activity of the level seen at MC4R, which explains why AgRP's inverse agonism at MC3R is quantitatively smaller. In the hypothalamic arcuate nucleus, MC3R is expressed on AgRP/NPY neurons (autoreceptor function) - MC3R activation inhibits AgRP neuron activity, reducing downstream AgRP release and amplifying the net melanocortin tone. Peripheral MC3R in macrophages and monocytes: Gs/cAMP → suppression of NF-κB → reduced TNF-α, IL-6, IL-1β - part of the mechanism underlying Acthar Gel's anti-inflammatory effects. MC3R knockout in rodents: increased fat mass, reduced lean mass, blunted response to caloric restriction, suggesting a role in energy efficiency rather than acute appetite control.

No MC3R-selective agonist or antagonist has reached clinical approval. γ-MSH derivatives and cyclic heptapeptide scaffolds such as MTII (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) activate MC3R/MC4R with moderate MC3R preference in selectivity scans, but true MC3R selectivity remains an unsolved challenge because the binding pockets of MC3R and MC4R are highly homologous. For peptide research, the tractable recipes are: γ-MSH(1-12) analogs with backbone N-methylation or D-amino acid substitutions at positions flanking the HFRW core to bias toward MC3R vs MC4R; cyclic MSH scaffolds with selective constraints at ECL2-contact positions that exploit the few residues distinguishing the MC3R and MC4R binding pockets; and MC3R agonist peptides conjugated to central nervous system delivery vectors (cell-penetrating peptide fusions, intranasal formulations) for hypothalamic autoreceptor modulation in metabolic syndrome research.